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Abstract
Background: Nociceptin/orphanin FQ and its receptor (NOP) are involved in immune responses, inflammation and pain
processing. The aim of this study was to investigate the modulation of NOP and prepro-nociceptin (PNoc), the precursor of
nociceptin, by inflammatory mediators in human whole blood.
Methods: Peripheral blood from healthy volunteers was cultured for 0, 3, 6 and 24 hrs with or without lipopolysaccharide
(LPS), tumor necrosis factor (TNF)-a, interleukin (IL)-1b, IL-10 or interferon (IFN)-c. NOP and PNoc mRNA of peripheral white
blood cells were detected by quantitative RT-PCR. Cytokine concentrations in supernatants of whole blood cultures were
measured using ELISA. In addition, an intervention experiment using anti-cytokine antibodies was conducted to evaluate
possible mechanisms involved in the modulation of NOP and PNoc by LPS. The primary goal was to investigate NOP and
PNoc mRNA expression in human peripheral blood under inflammatory conditions.
Results: LPS significantly suppressed NOP (median area under the mRNA-expression-time curve (1st/3rd quartile): 5.4 (4.6/
6.6) normalized ratio ? hr) and PNoc expression (40.8 (34.4/49.5)) compared to baseline measures (NOP: 22.7 (17.1/25.3);
PNoc: 69.9 (58.4/89.2), both p,0.001). LPS incubation induced cytokine concentrations (TNF-a, IL-1b, IL-10 and IFN-c) in
whole blood cultures. Incubation with TNF-a, IL-1b, IL-10 or IFN-c decreased NOP mRNA levels to varying extents (p,0.05
for all). In contrast, PNoc mRNA expression was decreased by IL-10 only (p = 0.018). The LPS effect on NOP expression could
be antagonized by anti-TNF-a and anti-IL-1b, whereas anti-IL-10 and anti-INF-c had no effect. There was no change of PNoc
expression when LPS induced cytokines were antagonized by the respective antibodies.
Conclusions: LPS as well as cytokines suppress mainly NOP and, in part, PNoc mRNA expression in human whole blood
cultures. This may represent a negative feedback loop to the previously described upregulation of cytokines by PNoc.
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Introduction
Nociceptin receptor (NOP) is a G-protein-coupled receptor
sharing high homology with classic opioid receptors. Nociceptin/
orphanin FQ, a 17-amino-acid neuropeptide, is the endogenous
ligand of NOP. The nociceptin-NOP system is involved in a wide
range of physiological processes, including inflammation and pain
[1,2]. Studies have demonstrated the complex involvement of the
nociceptin-NOP activation in pain pathways producing hyperal-
gesia when administered supraspinally and evoking analgesia
when administered at the spinal site [3]. The distribution of NOP
and nociceptin and their activity in the immune system suggest
that the ligand and its receptor might be regulatory elements in
immune modulation [3,4].
A previous study revealed that nociceptin expression is
regulated by injury-induced stimuli [5]. Lipopolysaccharide
(LPS) as well as tumor necrosis factor (TNF)-a and interleukin
(IL)-1b effect nociceptin expression by activating various signaling
pathways in astrocytes [6]. Both NOP and nociceptin were
detected in human peripheral blood [7,8]. Moreover, up- and
down-regulation of nociceptin and its receptor in peripheral blood
of patients with pain or inflammatory diseases have been reported
[9–12]. Up to now, numerous studies have extensively investigated
the expression of NOP and nociceptin in the nervous system
[6,13–16], while much less is known about their modulation in
whole blood under inflammatory conditions.
LPS is a major structural feature of gram-negative bacteria and
has been found to be a potent inductor of immune responses [17].
Release of some cytokines like TNF-a, IL-1b, IL-10 and IFN-c is
induced in LPS-challenged human whole blood [18]. In the
present trial, changes of mRNA expression in NOP and prepro-
nociceptin (PNoc), the precursor of nociceptin, in human white
blood cells influenced by inflammatory mediators were investigat-
ed. The hypothesis was that inflammatory signals modulate NOP
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and PNoc mRNA expression in human whole blood and that LPS
induced effects are mediated by endogenous cytokines.
Materials and Methods
Ethics Statement
After approval by the Ethics Committee of the Canton of Bern
(KEK 041/09) and participants’ written informed consent, 30
healthy volunteers were enrolled in this observational ex vivo study.
Exclusion criteria were lack of informed consent, age younger than
18 years, pregnancy, fever, acute infection or a history of
inflammatory disease during the last four weeks before the study,
as well as any regular intake of medication including antibiotics.
Blood Culture
All heparinized peripheral blood samples were drawn between
07:00 and 08:00 a.m. Undiluted whole blood was cultured in flat-
bottomed 24-well culture plates (Greiner Bio-One, Frickenhausen,
Germany) at a volume of 900 ml per well prior to the addition of
test agents. All agents were diluted with RPMI 1640 medium
supplemented with 10% heat-inactivated fetal calf serum, 100
units/ml penicillin and 100 mg/ml streptomycin (all from Sigma,
Mannheim, Germany) and prepared freshly from the stock
concentration for each experiment. Cultures were incubated at
37uC in a 5% CO2 atmosphere. At each indicated incubation time
point, cultured cells were harvested, centrifuged at 1500 g for 5
minutes. Subsequently, peripheral white blood cells were collected
for RNA isolation, whereas the supernatants were stored at
280uC for further analysis of cytokine concentrations.
The impact of LPS and IL-10 on both NOP and PNoc mRNA
expression in peripheral blood cells was initially tested (n = 9).
Experiments of dose-dependency effects of LPS and cytokines
were performed (n= 4 for each experiment). According to the
results of these experiments, blood was cultured using the
appropriate concentrations of LPS and cytokines (n = 7). To
further investigate the role of the cytokines involved in these
cultures, an intervention experiment was conducted (n= 10).
Dose - response experiments. Whole blood was analyzed
for NOP and PNoc mRNA expression after incubation with or
without LPS (6 hrs) and various cytokines (3 hrs). For these dose-
response experiments, LPS 0.5–104 pg/ml (from E. coli O127:B8,
Sigma, Steinheim, Germany), TNF-a 1–10 ng/ml, IL-1b 1–
10 ng/ml, IL-10 0.5–50 ng/ml and IFN-c 1–20 ng/ml (all from
R&D Systems, Oxford, UK) were used.
Whole blood cultured with inflammatory
mediators. According to the results of the dose-response
experiments and findings from previous studies [18], LPS
10 ng/ml, TNF-a 3 ng/ml, IL-1b 3 ng/ml, IL-10 50 ng/ml and
IFN-c 10 ng/ml were used in the subsequent whole blood
cultures. Incubation times were set to 0, 3, 6 and 24 hrs. A
control group without any additional stimuli was included in each
experiment.
Intervention experiment. Blood from ten volunteers was
used for the intervention experiment. To possibly antagonize the
cytokines induced by LPS in whole blood, neutralizing monoclonal
antibodies (mAbs) to human TNF-a or IL-1b or IL-10 or IFN-c or
the combination TNF-a+IL-1b (all from R&D Systems, Oxford,
UK) were added at a final concentration of 5 mg/ml 30 minutes
prior to the treatment of LPS (50 pg/ml). In addition, blood
incubated with LPS+isotype Ab 5 mg/ml as well as blood without
any stimulant was cultured. Isotype Ab was chosen as control
group to estimate the non-specific binding of target antibodies due
to crystallisable fragment receptor binding, or other protein-
protein interactions according to the immunoglobulin type of the
antibodies used in the present study. NOP and PNoc mRNA
expression were assessed after the blood was incubated for 3, 6 and
24 hrs with LPS and the respective antibodies.
RNA Isolation, cDNA Synthesis and Relative
Quantification
Total RNA of whole white blood cells collected at the different
incubation time points was isolated according to the QIAamp
RNA Blood Mini Kit instructions (Qiagen, Hilden, Germany).
Briefly, red blood cells were lysed with the erythrocyte lysis buffer;
subsequently leucocytes were lysed and homogenized, and the
lysate was loaded onto a column for total RNA binding. After
wash steps, RNA was eluted and the concentration was
determined by optical densitometry at 260/280 nm. cDNA was
synthesized using the 1st Strand cDNA Synthesis Kit for RT-PCR
avian myeloblastosis virus (AMV) (Roche, Mannheim, Germany)
according to the manufacture’s protocol.
The relative mRNA levels of NOP and PNoc were determined
by quantitative RT-PCR. Expression of NOP, PNoc and the
reference gene human hypoxanthine phosphoribosyl-transferase
(HPRT) were detected in separate capillaries as duplicates on a
LightCycler 2.0 (Roche, Mannheim, Germany). cDNA prepared
from the SK-N-DZ cell line was used as a calibrator.
The cDNA was subjected to PCR amplification in 20 ml
reaction volume containing 4 ml of LightCyclerH FastStart DNA
MasterPLUS SYBR Green I (Roche, Mannheim, Germany) and
10 pmol of each primer (TIB MOLBIOL, Berlin, Germany) for
NOP and PNoc. For HPRT, 16 nM of universal probe #73
(Roche, Mannheim, Germany), 4 ml LightCyclerH TaqManH
Master (Roche, Mannheim, Germany) and 10 pmol of each
primer (TIB MOLBIOL, Berlin, Germany) were used. The
sequence of primers and PCR conditions have been described
previously [7,10,19]. Primer sequences were as follows: HPRT, 59-
TGACCTTGATTTATTTTGCATACC-39 and 59-CGAGCAA-
GACGTTCAGTCCT-39; NOP, 59-
TGCCGTTCTGGGAGGTTATCTA-39 and 59-TTAGGGT-
GAAGGTGCTGGTGA-39; PNoc, 59-CCTGCACCA-
GAATGGTAATG-39 and 59-GCTGAGCACATGCTGTTTG-
39. The mRNA expression of NOP and PNoc was analyzed by the
LightCycler Relative Quantification Software (Roche Diagnostics,
Mannheim, Germany). In the present study, standard curves used
to control the efficiency of PCR were generated by PCR
amplification of NOP, PNoc and HPRT in a series of diluted
cDNA in triplicates, respectively. Data of real-time PCR, including
calibrator and samples, were analyzed using the LightCycler
Relative Quantification Software. NOP and PNoc mRNA levels
were expressed as the target/reference ratio of each sample
normalized by the target/reference ratio of the calibrator used in
the PCR reactions (normalized ratio) [20].
Enzyme-linked Immunosorbent Assay (ELISA)
Supernatants of whole blood cultures were collected at pre-
defined time points. The amounts of TNF-a, IL-1b and IL-10
protein were measured using human TNF-a/TNFSF1A, IL-1b/
IL-1F2 and IL-10 Quantikine ELISA kits (all from R&D Systems,
Oxford, UK) according to the manufacturer’s instructions. To
detect IFN-c, the human IFN-c platinum ELISA kit (eBioscience,
Vienna, Austria) was applied. Briefly, supernatants of the cultures
were appropriately diluted before proceeding with the ELISA
measurement according to the detection range of the assay.
Samples were measured in duplicates and a standard curve was
created for each plate. The absorbance was read at 450 nm by an
ELISA-Reader (Bio-Rad Lab., USA). The results were assessed by
calculating the values of coefficient of variation to compare mean
Nociceptin and Its Receptor mRNA in Human Blood
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concentrations. Minimum detection levels were 15.6 pg/ml for
TNF-a, 3.9 pg/ml for IL-1b, 7.8 pg/ml for IL-10 and 0.99 pg/ml
for IFN-c.
Statistical Analysis
mRNA results are presented as the median normalized ratio
(1st/3rd quartile) or as the area under the mRNA-expression-time
curve (AUC normalized ratio N hr; time points: 0, 3, 6 and 24 hrs).
The primary endpoint was the comparison of AUCs of NOP and
PNoc mRNA under co-incubation with different stimuli compared
to baseline expression. The Mann-Whitney U and the Kruskal-
Wallis tests were applied and p,0.05 was considered as
statistically significant with results being corrected for multiple
testing. Cytokine concentrations are presented as mean6SD and
compared by ANOVA.
Results
Study Subjects
13 female and 17 male healthy volunteers, aged 26–50 years,
participated in the present study.
Modulation of NOP and PNoc Expression by
Inflammatory Mediators
NOP and PNoc mRNA were constitutively expressed in
peripheral blood cells of all healthy volunteers (median normalized
ratio (1st/3rd quartile): 1.1 (0.8/1.3) and 5.4 (4.2/6.5)). LPS dose-
dependently down-regulated NOP and PNoc expression at a
concentration range between 0.5–104 pg/ml with an EC50 of
15 pg/ml (logEC50 = 1.260.1) for NOP and 41 pg/ml (lo-
gEC50 = 1.6696.4) for PNoc (Figure 1). The co-incubation of
whole blood with pro-inflammatory cytokines (TNF-a, IL-1b and
IFN-c) induced a dose-dependent reduction of NOP mRNA
levels.
Results addressing NOP and PNoc mRNA expression under co-
incubation with inflammatory mediators calculated as AUC are
presented in Table 1. A significant decrease of NOP expression by
LPS, TNF-a, IL-1b, IL-10 and IFN-c was induced compared to
the respective controls. LPS effects were most pronounced with a
decrease of NOP expression to 12.0 (8.3/25.8)% at 3 hrs and to
5.5 (3.0/13.0)% at 6 hrs compared to controls without co-
incubation (both p,0.001). Measures at 3 hrs for IL-10 treated
samples were 46.5 (27.8/74.5)%, for TNF-a 31.0 (26.0/41.0)%,
for IL-1b 82.0 (59.0/86.0)% and for IFN-c treated samples 49.5
(43.5/53.5)% compared to controls without co-incubation (all
p,0.03).
For PNoc expression, a suppression of mRNA expression was
only observed for LPS (36.5 (19.3/52.5)% of controls at 3 hrs;
p,0.001) and IL-10 (48.5 (42.5/59.0)% of controls; p,0.001). For
blood co-incubated with TNF-a, IL-1b or IFN-c, the level of
significance was not met in the AUC analysis (Table 1).
Concentrations of Cytokines in LPS-induced Whole Blood
Cells
To verify LPS effects within the whole blood cultures, cytokine
concentrations were measured in culture supernatants. Before
stimulation as well as after incubation without stimuli, cytokine
concentrations were below the detection limit. After co-incubation
with LPS 10 ng/ml for 3 hrs, the concentrations of TNF-a and
IL-1b in the supernatants increased. IFN-c was detectable in the
samples after 3 hrs and increased after 6 hrs, whereas IL-10 was
detected after 6 hrs of LPS stimulation (Table 2).
Interventions
The effects of anti-TNF-a, anti-IL-1b, anti-IL-10 and anti-IFN-
c mAbs on the expression of NOP and PNoc were investigated in
LPS-challenged whole blood (Figure 2). After 3 hrs of incubation,
the suppressive effect of LPS on NOP could be partially prevented
by co-incubation of antibodies antagonizing TNF-a or IL-1b or
both (Figure 2A). Anti-TNF-a, anti-IL-1b and the combination of
these two antibodies increased NOP mRNA expression 1.6 (95%
CI: 1.2–2.0), 1.4 (1.0–1.6) and 1.8 (1.4–2.1)-fold compared to
‘‘LPS+isotype Ab’’ control. The combination led to a stronger
recovery of NOP expression when compared to the group treated
with anti-IL-1b only (p = 0.0075), while the difference did not
reach statistical significance when compared to the group with
anti-TNF-a only.
However, these preventive effects were not observed after 6 and
24 hrs of incubation. As to PNoc expression, none of the anti-
Figure 1. Effects of LPS on NOP and PNoc mRNA expression. Whole blood was cultured without LPS or with increasing concentrations of LPS
0.5–104 pg/ml for 6 hrs. LPS suppressed both NOP and PNoc mRNA expression. Data are presented as medians with interquartile ranges. n = 4,
Kruskal-Wallis test with subsequent post hoc analysis, *: p,0.05. LPS, lipopolysaccharide; NOP, nociceptin receptor; PNoc, nociceptin precursor.
doi:10.1371/journal.pone.0074138.g001
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cytokine antibodies antagonized the LPS induced down-regula-
tion, neither at 3 hrs (Figure 2B) nor at 6 and 24 hrs.
In summary, the LPS-induced reduction on NOP and PNoc
expression was mediated by different cytokines for each target
(Table 3).
Discussion
Previous work underlines the role of the nociceptin-NOP system
in inflammatory response and nociceptive pathways [3,14,21–23].
However, NOP and nociceptin have also been implicated in a
wide range of physiological and behavioral functions, e.g.
pathways of inflammation, pain, anxiety, fear, stress, tolerance,
dependence, locomotion, feeding, learning and memory
[1,3,10,12,24]. Thus, NOP is discussed as promising target of
pharmacological research [10,25]. As NOP and nociceptin are
expressed in the human central nervous system as well as in
immune cells at similar levels, they are discussed as important
mediators of pain perception and immune responses with possible
involvement in the brain-immune axis [14,26]. Understanding the
regulation of nociceptin and its receptor NOP is crucial for gaining
knowledge and competence to modulate the nociceptin-NOP
system. Pain management, modulation of inflammatory processes,
e.g. inflammatory disease of the airway [27], may represent future
areas in which basic understanding of the activation, expression as
well as suppression can be translated to clinical strategies to
minimize pain or interfere with inflammation.
Modulation of NOP and PNoc in Inflammatory Conditions
The current RT-PCR analysis revealed that LPS significantly
suppressed NOP and PNoc mRNA expression in human whole
blood cells via an LPS-induced upregulation of specific cytokines.
Experiments with cytokine antibodies revealed TNF-a and IL-1b
as modulators of NOP mRNA expression. Previous findings on
NOP and/or nociceptin were inconsistent for other organs: LPS
suppressed NOP expression in rats’ basal forebrain and decreased
NOP mRNA transcripts in the cerebral cortex, hippocampus and
hypothalamus in a severe stressor model [28]. After challenging
with staphylococcal enterotoxin A (SEA), NOP and PNoc
expression were reduced in spleens of mice, while they were
induced in the thymus [24]. On the other hand, nociceptin mRNA
was up-regulated by LPS in rat astrocytes and in mice sensory
neuron cultures and NOP expression was strongly induced after
activation of human lymphocytes by phytohaemagglutinin
[13,15,26]. Williams and co-workers [7,8] reported of NOP and
PNoc mRNA expression in human peripheral blood mononuclear
cells, whereas other authors described NOP mRNA expression on
human granulocytes, lymphocytes and monocytes and nociceptin
transcripts in resting human peripheral blood lymphocytes,
specifically CD19+ B cells [29,30].
Both in vitro and in vivo studies have supported the evidence that
NOP and nociceptin play a role in systemic inflammatory
reactions and sepsis [11]. However, studies in humans have been
conflictual: Decreased nociceptin plasma protein has been
reported in fibromyalgia-syndrome patients compared to controls
[9]. In contrast, protein concentrations were high in acute and
chronic pain states as well as in septic patients [12,31]. A
comparison between critically ill patients and healthy controls
revealed significant differences in NOP and PNoc mRNA levels in
peripheral blood cells [10]. Constitutive NOP mRNA expression
was increased in cancer patients, postoperative patients, and septic
patients, with highest levels in end-stage cancer patients. In
contrast, PNoc expression was reduced in cancer and septic
patients but not in postoperative patients [10]. In addition, ex vivo
Table 1. AUC of NOP and PNoc mRNA expression (median normalized ratio hr with 1st/3rd quartiles) after whole blood was co-
cultured with different stimuli for 0, 3, 6 and 24 hrs.
Stimulation n NOP expression pa PNoc expression pa
Control without co-incubation 20 22.7 (17.1/25.3) 69.9 (58.4/89.2)
LPS 10 ng/ml 20 5.4 (4.6/6.6) 0.001 40.8 (34.4/49.5) 0.001
IL-10 50 ng/ml 16 12.5 (6.1/16.0) 0.001 51.5 (40.3/59.0) 0.018
TNF-a 3 ng/ml 7 10.4 (9.5/12.4) 0.002 48.4 (28.6/65.0) 0.109
IL-1b 3 ng/ml 7 14.3 (13.6/17.4) 0.032 50.5 (36.1/73.8) 0.433
IFN-c 10 ng/ml 6 11.1 (10.6/12.1) 0.002 65.8 (53.7/91.1) 0.828
aComparison to blood cultures without any co-incubation; Mann-Whitney U test, p-values were corrected for multiple testing.
doi:10.1371/journal.pone.0074138.t001
Table 2. TNF-a, IL-1b, IL-10 and IFN-c concentrations (pg/ml) in supernatants of whole blood cultures incubated with LPS 10 ng/
ml.
Cytokine Before stimulation 3 hrs LPS stimulation for 6 hrs 24 hrs
TNF-a ,15.6 7077.763404.3a 10768.1±4967.6a 4321.063436.7a
IL-1b ,3.9 915.56981.7a 6392.163211.2a 7535.7±3438.5a
IL-10 ,7.8 ,7.8 224.06290.2b 3334.0±1210.8a
IFN-c ,1.0 12.1616.4 194.46134.4a 653.9±438.3a
Data are presented as mean6SD, n = 19. Maximum levels are printed in bold.
aANOVA p,0.001,
bp,0.05 compared to the respective cytokine concentration before stimulation.
doi:10.1371/journal.pone.0074138.t002
Nociceptin and Its Receptor mRNA in Human Blood
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findings showed that nociceptin stimulated human monocyte
chemotaxis and exerted a modulatory role on T cell functions [4].
All these findings supported the evidence that NOP and nociceptin
are regulatory elements in immune response. Taken together,
different pathological states and study cohorts or cellular
subpopulations and varying measurements (e.g., RNA versus
protein) might contribute to the wide range of previous findings.
Suppression as well as up-regulation can occur and it is worthwhile
to examine underlying mechanisms more closely.
LPS Model
The LPS model was chosen as LPS induces a variety of pro- as
well as anti-inflammatory mediators in human peripheral blood,
with TNF peaking at 60 to 90 minutes and IL-1b at 3–4 hrs after
initiation of LPS stimulation ex vivo as well as in vivo [18,32,33].
The present ELISA results are in line with these findings, as well as
the kinetics of partial prevention of LPS induced NOP suppression
with anti-TNF-a or/and anti-IL-1b mAb at 3 hrs. Thus, the
intervention experiments support the hypothesis that cytokines like
TNF-a, IL-1b are potent modulators of NOP expression in white
blood cells induced by LPS. Previous studies have reported that
signaling pathways via ERK, p38 and NF-kB are involved in the
upregulation of PNoc expression by LPS in rat astrocytes. It has
yet to be assessed which signal transduction cascades are involved
in human cells. This knowledge can, in turn, be used to interfere
with nociceptin activity in vivo.
Figure 2. Intervention study. Percent change of NOP (A) and PNoc (B) mRNA expression in whole blood cells after incubation with LPS+anti-TNF-a
5 mg/ml, LPS+anti-IL-1b 5 mg/ml, LPS+anti-TNF-a 5 mg/ml+anti-IL-1b 5 mg/ml, LPS+anti-IL-10 5 mg/ml, LPS+anti-IFN-c 5 mg/ml, LPS+isotype control
5 mg/ml (dashed line set to 100%) or without any treatment (untreated) for 3 hrs. Box plots show medians (horizontal lines), interquartile ranges
(boxes) and 5th/95th percentiles (error bars). n = 10, Mann-Whitney U test, *: p,0.01, **: p,0.001, corrected for multiple testing. LPS,
lipopolysaccharide; NOP, nociceptin receptor; PNoc, nociceptin precursor; TNF, tumor necrosis factor; IL, interleukin; IFN, interferon.xl.
doi:10.1371/journal.pone.0074138.g002
Table 3. Effects of various stimuli on NOP and PNoc mRNA
expression in human whole blood.
Stimulation NOP mRNA PNoc mRNA
LPS 10 ng/ml QQQ QQ
IL-10 50 ng/ml QQ Q
TNF-a 3 ng/ml QQ R
IL-1b 3 ng/ml QQ R
IFN-c 10 ng/ml QQ R
Suppressive effect: Q, ,25%; QQ, ,50%; QQQ, ,75%; R, no significant
change compared to base line.
doi:10.1371/journal.pone.0074138.t003
Nociceptin and Its Receptor mRNA in Human Blood
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Culturing blood with LPS for 6 or 24 hrs induced a variety of
cytokines, including pro- as well as anti-inflammatory cytokines
(i.e. TNF, IL-1b, IFN-c, IL-10) and other mediators released from
peripheral blood cells. The observed inhibition of NOP expression
was possibly due to an additive effect of inflammatory mediators in
the blood culture at these specific time points. The partial
blockade indicated that these cytokines are only part of the
pathway responsible for modulation of NOP expression. IL-10, for
example, also suppressed NOP; however, this cytokine is induced
rather late by LPS. In addition, the binding of the neutralizing
antibody possibly resulted in decreased free antibody concentra-
tions at 6 and 24 hrs. These lower antibody concentrations might
be unable to completely antagonize newly synthesized cytokines in
the cultures. In contrast, the lacking neutralizing effect on LPS-
induced PNoc suppression by anti-TNF-a and anti-IL-1b at 3 hrs
indicates a differential regulation of NOP and PNoc.
NOP, PNoc and Cytokines
Gavioli and colleagues [34] summarized in their review that the
activation of nociceptin-NOP signaling might induce production
of inflammatory mediators, which leads to altered expression of
cytokines. The present trial used a reversed approach with LPS/
cytokines mediating NOP and PNoc. Interestingly, increase of
TNF-a and IL-1b concentrations, but not IL-10 in plasma after
administration of nociceptin has been also reported in a rat model
with sepsis [35]. As TNF-a and IL-1b mediate most of the
physiological disturbances which are characteristic for sepsis, it is
possible that the down-regulation of PNoc and NOP in peripheral
blood cells might restrict the production of pro-inflammatory
cytokines. The observed suppression of PNoc expression is in line
with the lower nociceptin precursor mRNA detected in peripheral
blood cells from septic patients previously [10]. This might
indicate a regulation loop and/or negative feedback between the
NOP-system and cytokines.
The mechanisms of immunoregulation and inflammation by
cytokines are in part established. However, modulation of PNoc by
cytokines has been investigated in animal models and cell lines
only [6,13,36]. In peripheral blood, cytokine signaling via a
restricted number of Jak-Stat pathways positively and negatively
regulates all cellular subsets during inflammation [37]. It has to be
shown whether similar signal transduction pathways are involved
when cytokines exert their effects on PNoc and NOP expression.
Compared to PNoc, NOP appeared to be more sensitive to
suppressive effects induced by pro- as well as anti-inflammatory
cytokines, at least during early inflammation. Animal studies
reported a clear suppressive effect of LPS on NOP in rat CNS
[28], whereas staphylococcal enterotoxin A suppressed NOP in
the spleen of mice [24]. During the later phases of sepsis (.24 hrs),
a variety of cytokines, chemokines and other inflammatory
mediators (either derived from peripheral blood cells or secreted
into the circulation by organ tissue), might influence the mRNA
expression of NOP in blood cells. The comprehensive effect of
these inflammatory substances on NOP might be an explanation
for NOP mRNA levels detected in peripheral blood from septic
patients [10]. Future studies should include an analysis of signal
transduction pathways to further elucidate the mechanistic
background of this phenomenon and define how the crosstalk
between cytokines, NOP and nociceptin works in human
peripheral white blood cells.
Limitations
Some limitations have to be mentioned. First, although LPS is
widely used to mimic inflammatory conditions in whole blood
cultures, the cultures may not accurately reflect the in vivo
pathophysiological changes under inflammatory conditions. Sec-
ond, modulation of NOP and PNoc expression in LPS-challenged
whole blood was analyzed only up to 24 hrs, and therefore,
expression patterns of NOP and PNoc during the later inflam-
matory phases are still unclear at this point. Third, no protein was
measured. This will be addressed in a future project.
Nevertheless, the present findings support the concept of strong
interactions between inflammation and the NOP-system. If NOP
ever becomes a therapeutic target, immunotherapy by cytokines
can down-regulate it. On the other hand, PNoc appears to be
regulated differently: Although LPS showed some effects on PNoc
expression, pro-inflammatory cytokines tested here do not
contribute to this effect. The different mechanisms of regulating
expression of PNoc and NOP have implications when differential
modulation of the nociceptin system is considered.
Conclusions
The present study demonstrated that mRNA expression of the
nociceptin receptor and of prepro-nociceptin is modulated
differently by inflammatory cytokines in human peripheral blood.
LPS and LPS-induced cytokines strongly suppressed NOP,
whereas the effects on prepro-nociceptin were minor.
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